The Interaction between Arachidonic Acid Metabolism and Homocysteine

Endocr Metab Immune Disord Drug Targets. 2021;21(7):1232-1241. doi: 10.2174/1871530320999200904130504.

Abstract

Hyperhomocysteinemia (HHcy) has been considered a risk factor for different diseases, including cardiovascular disease (CVD), inflammation, neurological diseases, cancer, and many other pathological conditions. Likewise, arachidonic acid (AA) metabolism is implicated in both vascular homeostasis and inflammation, as shown by the development of CVD, following the imbalance of its metabolites. This review summarizes how homocysteine (Hcy) can influence the metabolism of AA. In silico literature searches were performed on PubMed and Scopus as main sources. Several studies have shown that altered levels of Hcy, through AA release and metabolism, can influence the synthesis and the activity of prostaglandins (PGs), prostacyclin (PGI2), thromboxane (TXA), epoxyeicosatrienoic acids (EETs), and hydroxyeicosatetraenoic acids (HETEs). It is believed that by targeting Hcy in the AA pathways, novel compounds with better pharmacological and pharmacodynamics benefits may be obtained and that this information is valuable for a dietician to manipulate diets to improve health.

Keywords: Homocysteine; arachidonic acid; cardiovascular diseases; epoxyeicosatrienoic acids; homeostasis.; hyperhomocysteinemia.

Publication types

  • Review

MeSH terms

  • Animals
  • Arachidonic Acid / blood*
  • Biomarkers / blood
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Heart Disease Risk Factors
  • Homocysteine / blood*
  • Humans
  • Hyperhomocysteinemia / blood*
  • Hyperhomocysteinemia / diagnosis
  • Hyperhomocysteinemia / epidemiology
  • Prognosis
  • Risk Assessment

Substances

  • Biomarkers
  • Homocysteine
  • Arachidonic Acid